Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721199 | 0.91 | MCHR1 (0.32) | — | |
| SCHEMBL2719431 | 0.83 | RAB9A (0.35) | RAB9A | |
| SCHEMBL2719320 | 0.79 | ALDH1A1 (0.38) | NPC1RAB9AALDH1A1 | |
| SCHEMBL2825825 | 0.78 | NPC1 (0.31) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL4182186 | 0.77 | HRH3 (0.35) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL2828904 | 0.76 | HRH3 (0.32) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL22269082 | 0.73 | ALDH1A1 (0.51) | NPC1RAB9AMEN1ALDH1A1MAPK1 | |
| SCHEMBL2721657 | 0.73 | MCHR1 (0.38) | — | |
| SCHEMBL2828901 | 0.72 | — | — | |
| SCHEMBL2729618 | 0.72 | MCHR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144926-A1 | EPOXY RESIN COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| EP-2133379-A1 | EPOXY RESIN COMPOSITION | Sumitomo Chemical Company, Limited (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133380-A1 | RESIN COMPOSITION | Sumitomo Chemical Company, Limited (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20090054669-A1 | Process For Producing Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090018355-A1 | Process for Crystallizing an Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LTD. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018355-A1 | Process for Crystallizing an Epoxy Compound | PTGER1, NR5A1, TCP1 | NPC1 1690/4885CASP3 2499/4885RAB9A 3113/4885 |
| US-20090054669-A1 | Process For Producing Epoxy Compound | RER1, AR, CYP1A1 | NPC1 3654/4885CASP3 2090/4885RAB9A 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.